Autor: "Falcó V" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Disparities in Coronavirus Disease 2019 Clinical Outcomes and Vaccination Coverage Among Migrants With Human Immunodeficiency Virus in the PISCIS Cohort: A Population-Based Propensity Score-Matched Analysis.
Autorzy:: Nomah DK; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Díaz Y; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.; CIBER Epidemiologia y Salud Pública, Barcelona, Spain.
Bruguera A; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.; CIBER Epidemiologia y Salud Pública, Barcelona, Spain.; Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Moreno-Fornés S; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.; CIBER Epidemiologia y Salud Pública, Barcelona, Spain.
Aceiton J; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
Reyes-Urueña J; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.
Llibre JM; Fight Against Infections Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Falcó V; Infectious Disease Division, Hospital Universitari Vall D'Hebron, Barcelona, Spain.
Imaz A; HIV and STI Unit, Department of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain.
Fanjul FJ; Infectious Diseases Unit, Hospital Son Espases, Palma de Mallorca, Spain.
Peraire J; Hospital Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain.; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Deig E; Infectious Diseases Unit, Hospital General de Granollers, Granollers, Spain.
Domingo P; Department of Infectious Diseases, HIV Infection Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Inciarte A; Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Casabona J; Department de Salut, Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Generalitat de Catalunya, Badalona, Spain.; Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.; CIBER Epidemiologia y Salud Pública, Barcelona, Spain.; Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Miró JM; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.; Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.; Pokaż więcej
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jan 05; Vol. 11 (1), pp. ofad693. Date of Electronic Publication: 2024 Jan 05 (Print Publication: 2024).
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Autorzy:: Moreno S; Hospital Ramón y Cajal, CIBERINFEC, Universidad de Alcalá, IRYCIS, Madrid, Spain.
Rivero A; Hospital Reina Sofía, Córdoba, Spain.
Ventayol P; Hospital Son Espases, Palma, Spain.
Falcó V; Hospital Vall d'Hebron, Barcelona, Spain.
Torralba M; Hospital de Guadalajara, Guadalajara, Spain.
Schroeder M; ViiV Healthcare, Brentford, UK.
Neches V; Market Access, GSK, P.T.M Severo Ochoa, 2-28760, Tres Cantos, Madrid, Spain. .
Vallejo-Aparicio LA; Market Access, GSK, P.T.M Severo Ochoa, 2-28760, Tres Cantos, Madrid, Spain.
Mackenzie I; HEOR Ltd, Cardiff, UK.
Turner M; HEOR Ltd, Cardiff, UK.
Harrison C; HEOR Ltd, Cardiff, UK.; Pokaż więcej
Źródło:: Infectious diseases and therapy [Infect Dis Ther] 2023 Aug; Vol. 12 (8), pp. 2039-2055. Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.
Autorzy:: Grau-Expósito J; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Perea D; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Suppi M; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Massana N; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Vergara A; Nephrology Research Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Soler MJ; Nephrology Research Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Trinite B; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Autonomous University of Barcelona (UAB), Badalona, Spain.
Blanco J; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Autonomous University of Barcelona (UAB), Badalona, Spain.; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain.
García-Pérez J; AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Alcamí J; AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Clinic HIV Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Serrano-Mollar A; Experimental Pathology Department, Institut d'Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas (IIBB-CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Rosado J; Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, VHIR Task Force COVID-19, Barcelona, Spain.
Falcó V; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Genescà M; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.
Buzon MJ; Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain.; Pokaż więcej
Źródło:: PLoS pathogens [PLoS Pathog] 2022 Jan 13; Vol. 18 (1), pp. e1010171. Date of Electronic Publication: 2022 Jan 13 (Print Publication: 2022).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Virus Internalization*/drug effects
COVID-19 Drug Treatment*
Antiviral Agents/*therapeutic use
Lung/*virology
SARS-CoV-2/*physiology
Adult ; Animals ; Antiviral Agents/pharmacology ; COVID-19/immunology ; COVID-19/pathology ; Cells, Cultured ; Chlorocebus aethiops ; Drug Evaluation, Preclinical ; Drugs, Investigational/pharmacology ; Drugs, Investigational/therapeutic use ; HEK293 Cells ; Host-Pathogen Interactions/drug effects ; Humans ; Inflammation/pathology ; Inflammation/therapy ; Inflammation/virology ; Lung/pathology ; SARS-CoV-2/drug effects ; Vero Cells

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.
Autorzy:: Albasanz-Puig A; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Suanzes P; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Esperalba J; Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Fernández C; Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Sellarès-Nadal J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Torrella A; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Planas B; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Segura A; Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Burgos J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Ribera E; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Cañas-Ruano E; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
García JN; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Navarro J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Curran A; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Len Ó; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Falcó V; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Infectious Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.; Pokaż więcej
Źródło:: HIV medicine [HIV Med] 2021 Sep; Vol. 22 (8), pp. 682-689. Date of Electronic Publication: 2021 May 17.
Typ publikacji:: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytomegalovirus Infections*/epidemiology
HIV Infections*/complications
HIV Infections*/drug therapy
HIV Infections*/epidemiology
Adult ; CD4 Lymphocyte Count ; Cytomegalovirus ; Follow-Up Studies ; Humans ; Middle Aged ; Prevalence ; Viral Load ; Viremia

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Autorzy:: Palacio-Vieira J; Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain. .; CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain. .; Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. .
Reyes-Urueña JM; Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain.; CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain.; Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.
Imaz A; HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Spain.
Bruguera A; Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain.; Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.
Force L; Internal Medicine, Hospital de Mataró-Consorci Sanitari del Maresme, Mataró, Spain.
Llaveria AO; Internal Medicine, Hospital Verge de la Cinta de Tortosa, Tortosa, Spain.
Llibre JM; Infectious Diseases and 'Fight AIDS' Foundation, University Hospital Germans Trias i Pujol, Badalona, Spain.
Vilaró I; Hospital General de Vic, Vic, Spain.
Borràs FH; Hospital Son Llàtzer, Palma de Mallorca, Spain.
Falcó V; Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Riera M; Hospital Son Espases, Palma de Mallorca, Spain.
Domingo P; Hospital de Sant Pau, Barcelona, Spain.
de Lazzari E; HIV/AIDS Unit. Hospital Clinic, Barcelona, Spain.
Miró JM; HIV/AIDS Unit. Hospital Clinic, Barcelona, Spain.
Casabona J; Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain.; CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain.; Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.; Pokaż więcej
Corporate Authors:: PICIS study group
Źródło:: BMC public health [BMC Public Health] 2021 Aug 28; Vol. 21 (1), pp. 1596. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:: HIV Infections*/drug therapy
Lost to Follow-Up*
Developed Countries ; Humans ; Income

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence.
Autorzy:: Sellarès-Nadal J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Burgos J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Falcó V; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Almirante B; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.; Pokaż więcej
Źródło:: Journal of experimental pharmacology [J Exp Pharmacol] 2020 Nov 19; Vol. 12, pp. 529-538. Date of Electronic Publication: 2020 Nov 19 (Print Publication: 2020).
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.
Autorzy:: Curran A; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Rull A; Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, 43005 Tarragona, Spain.
Navarro J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Vidal-González J; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.; Department of Internal Medicine - Hepatology, Hospital Universitari Vall d'Hebron (HUVH), 08035 Barcelona, Spain.
Martin-Castillo M; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Burgos J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Falcó V; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Ribera E; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Torrella A; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Planas B; Vall d'Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain.
Peraire J; Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, 43005 Tarragona, Spain.
Crespo M; Internal Medicine Department. Complexo Hospitalario Universitario de Vigo; IIS Galicia Sur, 36312 Vigo, Spain.; Pokaż więcej
Źródło:: Journal of clinical medicine [J Clin Med] 2020 Apr 25; Vol. 9 (5). Date of Electronic Publication: 2020 Apr 25.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
Autorzy:: Grau-Expósito J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Luque-Ballesteros L; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Navarro J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Curran A; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Burgos J; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Ribera E; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Torrella A; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Planas B; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Badía R; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Martin-Castillo M; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Fernández-Sojo J; Banc de Sang i Teixits, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
Genescà M; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Falcó V; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Buzon MJ; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.; Pokaż więcej
Źródło:: PLoS pathogens [PLoS Pathog] 2019 Aug 19; Vol. 15 (8), pp. e1007991. Date of Electronic Publication: 2019 Aug 19 (Print Publication: 2019).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents/*pharmacology
CD4-Positive T-Lymphocytes/*immunology
HIV Infections/*immunology
HIV-1/*immunology
Virus Activation/*immunology
Virus Latency/*immunology
CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/virology ; Depsipeptides/pharmacology ; Diterpenes/pharmacology ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV-1/drug effects ; Humans ; Viral Load ; Virus Activation/drug effects ; Virus Latency/drug effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.
Autorzy:: Burgos J; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Curran A; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Landolfi S; Anatomical Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Navarro J; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Tallada N; Anatomical Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Guelar A; Internal Medicine Department, Mar University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
Crespo M; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Ocaña I; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Ribera E; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.
Falcó V; Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain.; Pokaż więcej
Źródło:: HIV medicine [HIV Med] 2016 Aug; Vol. 17 (7), pp. 524-31. Date of Electronic Publication: 2015 Dec 21.
Typ publikacji:: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Sexual and Gender Minorities*
Anus Neoplasms/*therapy
Electrocoagulation/*methods
HIV Infections/*complications
Squamous Intraepithelial Lesions of the Cervix/*therapy
Adult ; Female ; Humans ; Male ; Middle Aged ; Recurrence ; Treatment Outcome